300医药

Fosun Pharma Subsidiary's Levofloxacin Injection Approved

Fosun Pharma's Hengrui Medicine Receives Approval for Phase I Clinical Trial of HLX48 for Solid Tumors

Norges Bank Increases Stake in Pharmaron by 254,500 Shares, Latest Holding Ratio Reaches 7.07%

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

Hangzhou Topmed to Hold AGM on June 9 to Vote on Special Resolution for A-Share Buyback

JPMorgan Cuts Tigercat Profit Forecasts and Target Price to 39 HKD

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

Controlling Shareholder Investigated, Tigermed's 1 Billion Buyback Fails to Stop Stock Decline

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

China Renaissance Global Fund Increases Stake in Tigermed by 719,300 Shares on May 14 for HKD 25.84 Million

Schroders PLC Reduces Stake in Tigermed by 579,300 Shares on May 14

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Newly Revised 'Regulations on the Implementation of the Drug Administration Law' Takes Effect on May 15

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

Fosun Pharma: Expected to submit NDA by year-end

Baili Tianheng's Innovative Drug SI-B036 Approved for Clinical Trials in Late-Stage Solid Tumors by NMPA

Hengrui Medicine's Subsidiary Receives Approval for SHR-3079 Injection Clinical Trials

Hengrui Medicine Receives Approval for Three Drugs' Clinical Trials

中证医疗

159839

000037

560260

159837

512170

As of April 6, 112 biopharmaceutical companies in the A-share market have disclosed their annual reports, with 60 companies showing a year-on-year increase in net profit attributable to shareholders, among which 40 companies experienced growth in both revenue and net profit. Some companies have seen growth due to increased commercialization of innovative drugs and revenue from external licensing, while others are facing pressure due to strategic adjustments. Currently, the development characteristics of the pharmaceutical industry are evident, with deepening reforms on the payment side, innovative leaps on the supply side, restructuring of health service models, and diversification of consumer demand. Among the 40 companies with dual growth, 16 have seen a net profit increase of over 50%

腾讯新闻 - 财经

China Universal CNI BIOMEDICINE ETF

SSE Health Care

GF Fund CSI Medical Service ETF

E Fund CSI Biotechnology Theme ETF

Hwabao WP CSI Medical Service ETF

Biomedicine Sector Performance Scan: 40 Companies with Double Growth, 29 Companies with Double Decline, Driven by "Innovation + Going Global"

588250

516820

159859

588860

In 2025, the average number of employees in China's pharmaceutical manufacturing industry is expected to be 1.997 million, a decrease from 2.36 million in 2016. Since the drug review reform in 2015, China's biopharmaceutical industry has experienced rapid development, with a significant increase in the number of innovative drug applications and approvals. However, global tensions and market adjustments have posed challenges, leading to bottlenecks in industry development, and the decline in the average number of employees reflects this trend. Interviews with senior pharmaceutical headhunters provide profound insights into industry changes

Penghua SSE STAR Biology and Medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Tianhong CNI BIOMEDICINE ETF

ChinaAMC CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE Health Care ETF Initiating Fund

China Merchants CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

E Fund CSI Medical Service ETF

ICBCCS SSE STAR Biology and Medicine ETF

Tianhong Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drugs Selected 50 ETF

Minsheng Royal CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

CNI BIOMEDICINE

Yinhua CSI Innovative Drugs Industry ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

E Fund Hang Seng SCHK Innovative Drug ETF

E Fund CSI 300 Health Care ETF

Bosera Hang Seng Health Care ETF(QDII)

The halo of 'returnees' fades, large companies become internet-oriented, AI offers million-dollar salaries, 30 maxims about 2026 from a senior pharmaceutical headhunter

Since September last year, the pharmaceutical sector has undergone a deep adjustment, with the CSI 300 Pharmaceutical Index retreating over 18%. Recently, the pharmaceutical sector has shown strength against the trend, with some leading companies' stock prices reaching new highs. Analysis indicates that the pharmaceutical sector may have bottomed out, with marginal improvements in valuation and fundamentals. Future investments should focus on the innovative drug field, and although the macro environment remains uncertain in the short term, investment strategies should emphasize structural opportunities

Founder Fubon CSI Medicine and Medical Device Innovation ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Huaan Hang Seng Biotech ETF

GF CSI Innovative Drugs Industry ETF

Penghua CSI HK Connect Health Care Composite ETF

Has the pharmaceutical sector hit bottom this time? Which directions are worth paying attention to?

300医药(000913.SH)

Biomedicine Sector Performance Scan: 40 Companies with Double Growth, 29 Companies with Double Decline, Driven by "Innovation + Going Global"

The halo of 'returnees' fades, large companies become internet-oriented, AI offers million-dollar salaries, 30 maxims about 2026 from a senior pharmaceutical headhunter

Has the pharmaceutical sector hit bottom this time? Which directions are worth paying attention to?